See more : CP ALL Public Company Limited (CPALL.BK) Income Statement Analysis – Financial Results
Complete financial analysis of ZIM Laboratories Limited (ZIMLAB.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZIM Laboratories Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- MacKenzie Realty Capital, Inc. (MKZR) Income Statement Analysis – Financial Results
- CNNC International Limited (2302.HK) Income Statement Analysis – Financial Results
- Wide Open Agriculture Limited (WOA.AX) Income Statement Analysis – Financial Results
- Celon Pharma S.A. (CLN.WA) Income Statement Analysis – Financial Results
- C-Bond Systems, Inc. (CBNT) Income Statement Analysis – Financial Results
ZIM Laboratories Limited (ZIMLAB.BO)
About ZIM Laboratories Limited
ZIM Laboratories Limited develops, manufactures, and supplies generic pharmaceutical and nutraceutical products in India and internationally. The company provides its products in pre- formulation intermediates and finished formulations using modified release patterns in the oral solid dosage forms, such as granules, pellets, taste-masked powders, suspensions, tablets, capsules, dry syrup, and oral thin films. It offers therapeutics in the areas of urology, gastroenterology, CNS, antibiotics, anti-infectives, NSAIDs/pain analgesics, and vitamins and supplements. ZIM Laboratories Limited was incorporated in 1984 and is based in Nagpur, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.67B | 3.94B | 3.31B | 2.95B | 2.62B | 3.27B | 2.67B | 2.30B | 2.64B | 2.62B |
| Cost of Revenue | 2.41B | 2.00B | 1.61B | 1.59B | 1.45B | 1.60B | 1.41B | 1.20B | 1.58B | 1.83B |
| Gross Profit | 1.27B | 1.94B | 1.69B | 1.35B | 1.17B | 1.66B | 1.26B | 1.09B | 1.06B | 789.78M |
| Gross Profit Ratio | 34.48% | 49.29% | 51.25% | 45.93% | 44.66% | 50.93% | 47.10% | 47.61% | 40.09% | 30.17% |
| Research & Development | 0.00 | 187.38M | 168.75M | 138.67M | 145.17M | 153.09M | 93.74M | 81.38M | 57.21M | 0.00 |
| General & Administrative | 112.50M | 131.22M | 118.87M | 84.41M | 64.18M | 92.56M | 60.42M | 64.17M | 44.97M | 27.35M |
| Selling & Marketing | 244.80M | 279.38M | 326.98M | 279.63M | 245.08M | 456.11M | 282.22M | 225.32M | 220.38M | 166.99M |
| SG&A | 357.30M | 410.60M | 445.85M | 364.04M | 309.27M | 548.67M | 342.64M | 289.49M | 265.35M | 194.34M |
| Other Expenses | 655.76M | 4.40M | 1.77M | 1.73M | 2.09M | 2.49M | 9.62M | 33.29M | 15.86M | 12.00M |
| Operating Expenses | 1.01B | 1.59B | 1.44B | 1.11B | 1.07B | 1.35B | 982.41M | 852.26M | 840.89M | 642.48M |
| Cost & Expenses | 3.42B | 3.59B | 3.06B | 2.70B | 2.51B | 2.95B | 2.39B | 2.06B | 2.42B | 2.47B |
| Interest Income | 1.30M | 3.37M | 2.84M | 6.87M | 3.87M | 3.36M | 3.99M | 5.22M | 4.93M | 5.70M |
| Interest Expense | 69.24M | 49.70M | 71.69M | 95.10M | 113.31M | 87.47M | 84.38M | 99.59M | 109.60M | 86.72M |
| Depreciation & Amortization | 159.52M | 174.69M | 160.33M | 157.89M | 144.12M | 114.18M | 97.90M | 90.23M | 87.57M | 71.29M |
| EBITDA | 454.76M | 582.00M | 452.62M | 368.92M | 258.11M | 439.00M | 440.00M | 359.40M | 257.00M | 226.89M |
| EBITDA Ratio | 12.38% | 14.83% | 13.40% | 14.05% | 9.88% | 13.20% | 14.87% | 16.59% | 12.01% | 8.67% |
| Operating Income | 253.83M | 310.82M | 224.56M | 117.13M | 38.85M | 224.12M | 252.26M | 176.40M | 117.79M | 155.60M |
| Operating Income Ratio | 6.91% | 7.88% | 6.79% | 3.98% | 1.49% | 6.86% | 9.45% | 7.68% | 4.46% | 5.94% |
| Total Other Income/Expenses | -17.41M | 42.73M | -14.14M | -14.82M | -101.32M | -94.86M | -24.96M | -66.11M | -163.77M | -413.35M |
| Income Before Tax | 236.42M | 353.55M | 210.43M | 102.31M | 686.00K | 220.70M | 249.36M | 174.99M | 53.62M | -266.05M |
| Income Before Tax Ratio | 6.43% | 8.97% | 6.36% | 3.47% | 0.03% | 6.76% | 9.34% | 7.62% | 2.03% | -10.16% |
| Income Tax Expense | 63.96M | 109.21M | 64.92M | 29.14M | -32.28M | 67.29M | 58.26M | -10.87M | 2.65M | -49.97M |
| Net Income | 172.46M | 244.35M | 145.50M | 73.18M | 32.97M | 153.42M | 191.10M | 185.86M | 50.98M | -216.08M |
| Net Income Ratio | 4.69% | 6.20% | 4.40% | 2.48% | 1.26% | 4.70% | 7.16% | 8.09% | 1.93% | -8.25% |
| EPS | 3.54 | 5.01 | 2.99 | 1.50 | 0.68 | 3.17 | 3.96 | 3.85 | 1.06 | -4.47 |
| EPS Diluted | 3.54 | 5.01 | 2.99 | 1.50 | 0.68 | 3.15 | 3.93 | 3.82 | 1.05 | -4.44 |
| Weighted Avg Shares Out | 48.72M | 48.73M | 48.73M | 48.68M | 48.52M | 48.36M | 48.30M | 48.30M | 48.30M | 48.30M |
| Weighted Avg Shares Out (Dil) | 48.72M | 48.73M | 48.73M | 48.68M | 48.69M | 48.70M | 48.64M | 48.64M | 48.64M | 48.64M |
Source: https://incomestatements.info
Category: Stock Reports
How has ZIM Laboratories’ operating cash flow trended?
The cash flow statement of ZIM LABORATORIES reveals: Cash flow from operations decreased in FY24 and stood at Rs 163 m as compared to Rs 382 m in FY23. Cash flow from investments decreased in FY24 and stood at Rs -730 m as compared to Rs -362 m in FY23.